Implications of the FDA Draft Guidance on Biosimilars for Clinicians: What We Know and Don't Know

Journal of the National Comprehensive Cancer Network : JNCCN - United States
doi 10.6004/jnccn.2013.0052
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Harborside Press, LLC

Related search

Besnoitiosis in Caribou: What We Know and What We Don't Know

Rangifer
2011English

What We Know, What We Don't Know, and What We Need to Know About Welfare Reform

English

Circulating PTH Molecular Forms: What We Know and What We Don't

Kidney International
Nephrology
2006English

The Origin of Life: What We Know, What We Can Know and What We Will Never Know

Open Biology
BiochemistryImmunologyGeneticsMolecular BiologyNeuroscience
2013English

What We (Don't) Know About Global Plant Diversity

Ecography
EvolutionEcologySystematicsBehavior
2019English

Cancer Wars: How Politics Shapes What We Know and Don't Know About Cancer

Journal of Epidemiology and Community Health
EpidemiologyPublic HealthOccupational HealthEnvironmental
1997English

Assessing Risk in Pulmonary Arterial Hypertension: What We Know, What We Don't

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2017English

Quasicrystals. What Do We Know – What Can We Know?

Acta Crystallographica Section A: Foundations and Advances
Materials ScienceCondensed Matter PhysicsTheoretical ChemistryBiochemistryStructural BiologyInorganic ChemistryPhysical
2017English

Physical Activity in Pregnancy and Offspring Weight: What We Know and What We Don't

BJOG: An International Journal of Obstetrics and Gynaecology
GynecologyObstetrics
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy